The FDA approved the use of encorafenib (Braftovi, Pfizer) in combination with cetuximab (Erbitux, ImClone) in previously treated adults with BRAF V600E-mutated metastatic colorectal cancer (CRC).
APRIL 21, 2020
APRIL 21, 2020
The FDA approved the use of encorafenib (Braftovi, Pfizer) in combination with cetuximab (Erbitux, ImClone) in previously treated adults with BRAF V600E-mutated metastatic colorectal cancer (CRC).